FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2808092696> ?p ?o ?g. }

• W2808092696 abstract "There is increasing interest in the timely administration of concentrated sources of fibrinogen to patients with major traumatic bleeding. Following evaluation of early cryoprecipitate in the CRYOSTAT 1 trial, we explored the use of fibrinogen concentrate, which may have advantages of more rapid administration in acute haemorrhage. The aims of this pragmatic study were to assess the feasibility of fibrinogen concentrate administration within 45 minutes of hospital admission and to quantify efficacy in maintaining fibrinogen levels ≥ 2 g/L during active haemorrhage.We conducted a blinded, randomised, placebo-controlled trial at five UK major trauma centres with adult trauma patients with active bleeding who required activation of the major haemorrhage protocol. Participants were randomised to standard major haemorrhage therapy plus 6 g of fibrinogen concentrate or placebo.Twenty-seven of 39 participants (69%; 95% CI, 52-83%) across both arms received the study intervention within 45 minutes of admission. There was some evidence of a difference in the proportion of participants with fibrinogen levels ≥ 2 g/L between arms (p = 0.10). Fibrinogen levels in the fibrinogen concentrate (FgC) arm rose by a mean of 0.9 g/L (SD, 0.5) compared with a reduction of 0.2 g/L (SD, 0.5) in the placebo arm and were significantly higher in the FgC arm (p < 0.0001) at 2 hours. Fibrinogen levels were not different at day 7. Transfusion use and thromboembolic events were similar between arms. All-cause mortality at 28 days was 35.5% (95% CI, 23.8-50.8%) overall, with no difference between arms.In this trial, early delivery of fibrinogen concentrate within 45 minutes of admission was not feasible. Although evidence points to a key role for fibrinogen in the treatment of major bleeding, researchers need to recognise the challenges of timely delivery in the emergency setting. Future studies must explore barriers to rapid fibrinogen therapy, focusing on methods to reduce time to randomisation, using 'off-the-shelf' fibrinogen therapies (such as extended shelf-life cryoprecipitate held in the emergency department or fibrinogen concentrates with very rapid reconstitution times) and limiting the need for coagulation test-based transfusion triggers.ISRCTN67540073 . Registered on 5 August 2015." @default.
• W2808092696 created "2018-06-21" @default.
• W2808092696 creator A5010708955 @default.
• W2808092696 creator A5018342534 @default.
• W2808092696 creator A5018528746 @default.
• W2808092696 creator A5022437176 @default.
• W2808092696 creator A5022480314 @default.
• W2808092696 creator A5025909726 @default.
• W2808092696 creator A5040993027 @default.
• W2808092696 creator A5045400824 @default.
• W2808092696 creator A5048738726 @default.
• W2808092696 creator A5050750767 @default.
• W2808092696 creator A5057916363 @default.
• W2808092696 creator A5058558191 @default.
• W2808092696 creator A5067920302 @default.
• W2808092696 creator A5069889938 @default.
• W2808092696 creator A5081100117 @default.
• W2808092696 date "2018-06-18" @default.
• W2808092696 modified "2023-10-17" @default.
• W2808092696 title "Early fibrinogen concentrate therapy for major haemorrhage in trauma (E-FIT 1): results from a UK multi-centre, randomised, double blind, placebo-controlled pilot trial" @default.
• W2808092696 cites W1522407287 @default.
• W2808092696 cites W1599132736 @default.
• W2808092696 cites W1666870061 @default.
• W2808092696 cites W1823881053 @default.
• W2808092696 cites W1937601450 @default.
• W2808092696 cites W1939149497 @default.
• W2808092696 cites W1967433109 @default.
• W2808092696 cites W2080347790 @default.
• W2808092696 cites W2105743928 @default.
• W2808092696 cites W2126420535 @default.
• W2808092696 cites W2133226878 @default.
• W2808092696 cites W2133802104 @default.
• W2808092696 cites W2145517099 @default.
• W2808092696 cites W2147581820 @default.
• W2808092696 cites W2157199674 @default.
• W2808092696 cites W2173628117 @default.
• W2808092696 cites W2318359102 @default.
• W2808092696 cites W2323138975 @default.
• W2808092696 cites W2338438098 @default.
• W2808092696 cites W2344182848 @default.
• W2808092696 cites W2552876169 @default.
• W2808092696 cites W2554139698 @default.
• W2808092696 cites W2567516330 @default.
• W2808092696 cites W2609752450 @default.
• W2808092696 cites W2618849348 @default.
• W2808092696 cites W2686915446 @default.
• W2808092696 cites W2760460046 @default.
• W2808092696 cites W2793990421 @default.
• W2808092696 doi "https://doi.org/10.1186/s13054-018-2086-x" @default.
• W2808092696 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/6006766" @default.
• W2808092696 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/29914530" @default.
• W2808092696 hasPublicationYear "2018" @default.
• W2808092696 type Work @default.
• W2808092696 sameAs 2808092696 @default.
• W2808092696 citedByCount "65" @default.
• W2808092696 countsByYear W28080926962018 @default.
• W2808092696 countsByYear W28080926962019 @default.
• W2808092696 countsByYear W28080926962020 @default.
• W2808092696 countsByYear W28080926962021 @default.
• W2808092696 countsByYear W28080926962022 @default.
• W2808092696 countsByYear W28080926962023 @default.
• W2808092696 crossrefType "journal-article" @default.
• W2808092696 hasAuthorship W2808092696A5010708955 @default.
• W2808092696 hasAuthorship W2808092696A5018342534 @default.
• W2808092696 hasAuthorship W2808092696A5018528746 @default.
• W2808092696 hasAuthorship W2808092696A5022437176 @default.
• W2808092696 hasAuthorship W2808092696A5022480314 @default.
• W2808092696 hasAuthorship W2808092696A5025909726 @default.
• W2808092696 hasAuthorship W2808092696A5040993027 @default.
• W2808092696 hasAuthorship W2808092696A5045400824 @default.
• W2808092696 hasAuthorship W2808092696A5048738726 @default.
• W2808092696 hasAuthorship W2808092696A5050750767 @default.
• W2808092696 hasAuthorship W2808092696A5057916363 @default.
• W2808092696 hasAuthorship W2808092696A5058558191 @default.
• W2808092696 hasAuthorship W2808092696A5067920302 @default.
• W2808092696 hasAuthorship W2808092696A5069889938 @default.
• W2808092696 hasAuthorship W2808092696A5081100117 @default.
• W2808092696 hasBestOaLocation W28080926961 @default.
• W2808092696 hasConcept C126322002 @default.
• W2808092696 hasConcept C141071460 @default.
• W2808092696 hasConcept C142724271 @default.
• W2808092696 hasConcept C168563851 @default.
• W2808092696 hasConcept C204787440 @default.
• W2808092696 hasConcept C27081682 @default.
• W2808092696 hasConcept C2778258694 @default.
• W2808092696 hasConcept C2779036427 @default.
• W2808092696 hasConcept C42219234 @default.
• W2808092696 hasConcept C71924100 @default.
• W2808092696 hasConceptScore W2808092696C126322002 @default.
• W2808092696 hasConceptScore W2808092696C141071460 @default.
• W2808092696 hasConceptScore W2808092696C142724271 @default.
• W2808092696 hasConceptScore W2808092696C168563851 @default.
• W2808092696 hasConceptScore W2808092696C204787440 @default.
• W2808092696 hasConceptScore W2808092696C27081682 @default.
• W2808092696 hasConceptScore W2808092696C2778258694 @default.
• W2808092696 hasConceptScore W2808092696C2779036427 @default.
• W2808092696 hasConceptScore W2808092696C42219234 @default.
• W2808092696 hasConceptScore W2808092696C71924100 @default.
• W2808092696 hasFunder F4320310420 @default.
• W2808092696 hasIssue "1" @default.

• next